Literature DB >> 9329127

Gradual development of organ damage in the murine zymosan-induced multiple organ dysfunction syndrome.

M J Jansen1, T Hendriks, A A Verhofstad, W Lange, L M Geeraedts, R J Goris.   

Abstract

A well defined animal model is a prerequisite to test intervention strategies aimed at preventing the development of the multiple organ dysfunction syndrome. This study compares changes in clinical parameters to histopathologic changes in tissues, observed over a 12 day period after a single intraperitoneal injection of zymosan in C57BL/6 mice. Administration of zymosan induced gradual and progressive changes in wet and dry organ weight of the liver, kidneys, and particularly, lungs and spleen that correlated with increasing histopathology. From 6 days after zymosan injection onwards, hemorrhagic spots were found in the lungs evolving into massive hemorrhages at 12 days, when thickened interstitial walls and loss of the honey comb-like structures were observed. The liver displayed progressive accumulation of macrophage-like and mononuclear cells. After 12 days, numerous granuloma-like structures were disseminated throughout the liver parenchyma. The spleen displayed great changes in red and white pulp with increasing numbers of megakaryocytes and plasma-like cells. In the kidneys, necrosis of the tubular epithelium adjacent to granulomas on the ventral (peritoneal) side was found. In mice, a single intraperitoneal challenge with zymosan leads to progressive multiple organ damage, which becomes apparent at some time after the insult. This animal model displays a number of features encountered in human multiple organ dysfunction syndrome and appears suitable to conduct intervention studies.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9329127     DOI: 10.1097/00024382-199710000-00005

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  10 in total

1.  Melanocortins protect against multiple organ dysfunction syndrome in mice.

Authors:  Alessandra Bitto; Francesca Polito; Domenica Altavilla; Natasha Irrera; Daniela Giuliani; Alessandra Ottani; Letteria Minutoli; Luca Spaccapelo; Maria Galantucci; Renzo Lodi; Giuseppe Guzzo; Salvatore Guarini; Francesco Squadrito
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome.

Authors:  T J H Volman; R J A Goris; T Hendriks
Journal:  Intensive Care Med       Date:  2005-02-15       Impact factor: 17.440

3.  PD-L1 blockade improves immune dysfunction of spleen dendritic cells and T-cells in zymosan-induced multiple organs dysfunction syndromes.

Authors:  Qian Liu; Yi Lv; Min Zhao; Yiduo Jin; Jiangyang Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

4.  Dimethyl sulfoxide inhibits zymosan-induced intestinal inflammation and barrier dysfunction.

Authors:  Yu-Meng Li; Hai-Bin Wang; Jin-Guang Zheng; Xiao-Dong Bai; Zeng-Kai Zhao; Jing-Yuan Li; Sen Hu
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

5.  Epidermal growth factor reduces multiorgan failure induced by thioacetamide.

Authors:  M E Caballero; J Berlanga; D Ramirez; P Lopez-Saura; R Gozalez; D N Floyd; T Marchbank; R J Playford
Journal:  Gut       Date:  2001-01       Impact factor: 23.059

6.  Role of biphasic changes in splenic dendritic cell activity in a mouse model of multiple organ dysfunction syndrome.

Authors:  Yi Lv; Qian Liu; Min Zhao; Yiduo Jin; Jiangyang Lu
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

7.  Tissue- and time-dependent upregulation of cytokine mRNA in a murine model for the multiple organ dysfunction syndrome.

Authors:  Thomas J H Volman; R Jan A Goris; Jos W M van der Meer; Thijs Hendriks
Journal:  Ann Surg       Date:  2004-07       Impact factor: 12.969

8.  Inhibition of zymosan-induced kidney dysfunction by tyrphostin AG-490.

Authors:  Petya Dimitrova; Valeriya Gyurkovska; Irina Shalova; Luciano Saso; Nina Ivanovska
Journal:  J Inflamm (Lond)       Date:  2009-05-05       Impact factor: 4.981

9.  Regulatory T cells are protective in systemic inflammation response syndrome induced by zymosan in mice.

Authors:  Wenyuan Jia; Li Cao; Shuangwen Yang; Hailong Dong; Yun Zhang; Haidong Wei; Wei Jing; Lichao Hou; Chen Wang
Journal:  PLoS One       Date:  2013-05-10       Impact factor: 3.240

10.  Dectin-1 plays a redundant role in the immunomodulatory activities of β-glucan-rich ligands in vivo.

Authors:  Mohlopheni J Marakalala; David L Williams; Jennifer C Hoving; Rolf Engstad; Mihai G Netea; Gordon D Brown
Journal:  Microbes Infect       Date:  2013-03-19       Impact factor: 2.700

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.